CL2019001046A1 - Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131) - Google Patents

Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)

Info

Publication number
CL2019001046A1
CL2019001046A1 CL2019001046A CL2019001046A CL2019001046A1 CL 2019001046 A1 CL2019001046 A1 CL 2019001046A1 CL 2019001046 A CL2019001046 A CL 2019001046A CL 2019001046 A CL2019001046 A CL 2019001046A CL 2019001046 A1 CL2019001046 A1 CL 2019001046A1
Authority
CL
Chile
Prior art keywords
cancer
treatment
pharmaceutically active
mdm2 inhibitor
combination therapy
Prior art date
Application number
CL2019001046A
Other languages
Spanish (es)
Inventor
Sean Caenepeel
Jude Canon
Paul Hughes
Jonathan D Oliner
Richard J Rickles
Anne Y Saiki
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019001046A1 publication Critical patent/CL2019001046A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UNA TERAPIA DE COMBINACIÓN QUE INCLUYE UN INHIBIDOR MDM2 Y UNO O MÁS AGENTES FARMACÉUTICAMENTE ACTIVOS ADICIONALES, PARTICULARMENTE PARA EL TRATAMIENTO DE DISTINTOS TIPOS DE CÁNCER. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENE UN INHIBIDOR MDM2 Y UNO O MÁS AGENTES FARMACÉUTICAMENTE ACTIVOS ADICIONALES PARA EL TRATAMIENTO DE CÁNCERES.THIS INVENTION PROVIDES A COMBINATION THERAPY THAT INCLUDES AN MDM2 INHIBITOR AND ONE OR MORE PHARMACEUTICALLY ACTIVE ADDITIONAL AGENTS, PARTICULARLY FOR THE TREATMENT OF DIFFERENT TYPES OF CANCER. THE INVENTION ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS CONTAINING AN MDM2 INHIBITOR AND ONE OR MORE PHARMACEUTICALLY ACTIVE ADDITIONAL AGENTS FOR THE TREATMENT OF CANCER.

CL2019001046A 2014-11-11 2019-04-17 Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131) CL2019001046A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461902717P 2014-11-11 2014-11-11

Publications (1)

Publication Number Publication Date
CL2019001046A1 true CL2019001046A1 (en) 2019-06-28

Family

ID=67106721

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001046A CL2019001046A1 (en) 2014-11-11 2019-04-17 Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)

Country Status (1)

Country Link
CL (1) CL2019001046A1 (en)

Similar Documents

Publication Publication Date Title
CL2021001292A1 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CL2019000819A1 (en) Compounds and compositions to inhibit arginase activity. (divisional application 201801134)
CL2016001131A1 (en) Use of a pharmaceutical combination comprising an mdm2 inhibitor compound and one or more additional active agents for the treatment of cancer and pharmaceutical compositions comprising said combinations.
CO2019008487A2 (en) Quinazoline Compound
CL2018001358A1 (en) Compositions comprising bacterial strains
CL2018000198A1 (en) Compositions of transthyretin (ttr) arni and methods for use for the treatment or prevention of diseases associated with ttr
CY1125205T1 (en) ACTIVE PHARMACEUTICAL COMPOSITIONS FROM THE THERAPEUTIC POINT OF VIEW OF COMPOUNDS
CR20160538A (en) COMBINATION
BR112016018062A8 (en) therapeutic compounds, pharmaceutical composition and uses
HN2012000023A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CL2017002031A1 (en) Nasal powder formulation for the treatment of hypoglycemia
CL2020002624A1 (en) Stable anti-cd79b immunoconjugate formulations.
CO2019002245A2 (en) Fxr agonist combination
BR112018068027A2 (en) method for treating cancer in a patient and pharmaceutical composition
CL2018001157A1 (en) Formulation of fixed dose combination, eflornithine and sulindac.
CL2017002229A1 (en) Bace1 inhibitors.
CO2020003134A2 (en) Modulators of enac expression
CL2021003442A1 (en) Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer.
CL2019001046A1 (en) Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
CL2016003271A1 (en) Methods to treat infections
MX2020002812A (en) Abx196 for use in the treatment of bladder cancer.
CL2016002842A1 (en) S-mesylate salts and r-pirlindole pharmaceutical composition comprising them useful for the treatment of depression.
CR20160591A (en) METHODS TO TREAT INFECTIONS
UA101950U (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF COOL
UA101951U (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF COOL